CW July 2004
Volume 13Issue Number 7 July 2004 ISSN 10593802 Raloxifene May Protect Against Breast CancerRaloxifene (Evista), approved for the prevention and treatment of osteoporosis, may substantially reduce the risk of invasive breast cancer in post-menopausal women with osteoporosis. Among the more than 5,000 women in the trial, those who took the designer estrogen for 8 years reduced their risk by 59% compared to placebo.
Go to Previous Page Go to Next Page Source & Additonal Reading Silvana Martino of the Cancer Institute Medical Group in Santa Monica, CA, at the American Society of Clinical Oncology annual meeting Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
